286 related articles for article (PubMed ID: 27866063)
1. Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond.
Di Lisi D; Madonna R; Zito C; Bronte E; Badalamenti G; Parrella P; Monte I; Tocchetti CG; Russo A; Novo G
Int J Cardiol; 2017 Jan; 227():11-17. PubMed ID: 27866063
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular toxicity of biologic agents for cancer therapy.
Bhave M; Akhter N; Rosen ST
Oncology (Williston Park); 2014 Jun; 28(6):482-90. PubMed ID: 25134321
[TBL] [Abstract][Full Text] [Related]
3. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors.
Maurea N; Coppola C; Piscopo G; Galletta F; Riccio G; Esposito E; De Lorenzo C; De Laurentiis M; Spallarossa P; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e19-e26. PubMed ID: 27755239
[TBL] [Abstract][Full Text] [Related]
4. Cardio-oncology: management of cardiovascular toxicity.
Markman TM; Markman M
F1000Res; 2019; 8():. PubMed ID: 30755794
[TBL] [Abstract][Full Text] [Related]
5. Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors.
Dobbin SJH; Cameron AC; Petrie MC; Jones RJ; Touyz RM; Lang NN
Heart; 2018 Dec; 104(24):1995-2002. PubMed ID: 30228246
[TBL] [Abstract][Full Text] [Related]
6. Cardiotoxicity of molecular-targeted drug therapy.
Le DL; Cao H; Yang LX
Anticancer Res; 2014 Jul; 34(7):3243-9. PubMed ID: 24982327
[TBL] [Abstract][Full Text] [Related]
7. Genetic and ethnic modulation of cardiovascular toxicity of vascular endothelial growth factor inhibitors.
Chen YC; Chung CC; Lin YK; Chen YJ
Ann Med; 2018 Feb; 50(1):46-56. PubMed ID: 28929822
[TBL] [Abstract][Full Text] [Related]
8. Oxidative stress in anticancer therapies-related cardiac dysfunction.
Attanasio U; Pirozzi F; Poto R; Cuomo A; Carannante A; Russo M; Ghigo A; Hirsch E; Tocchetti CG; Varricchi G; Mercurio V
Free Radic Biol Med; 2021 Jun; 169():410-415. PubMed ID: 33930514
[TBL] [Abstract][Full Text] [Related]
9. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Langer CJ; Natale RB
Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
[TBL] [Abstract][Full Text] [Related]
10. Antineoplastic drugs inducing cardiac and vascular toxicity - An update.
Barachini S; Ghelardoni S; Varga ZV; Mehanna RA; Montt-Guevara MM; Ferdinandy P; Madonna R
Vascul Pharmacol; 2023 Dec; 153():107223. PubMed ID: 37678516
[TBL] [Abstract][Full Text] [Related]
11. The Molecular Mechanisms of Cardiotoxicity Induced by HER2, VEGF, and Tyrosine Kinase Inhibitors: an Updated Review.
Wu Q; Bai B; Tian C; Li D; Yu H; Song B; Li B; Chu X
Cardiovasc Drugs Ther; 2022 Jun; 36(3):511-524. PubMed ID: 33847848
[TBL] [Abstract][Full Text] [Related]
12. [Cardiotoxicity of cancer therapy].
Marek J; Linhart A; Rucklová Z; Haber J; Korínek J
Vnitr Lek; 2011 May; 57(5):472-84. PubMed ID: 21695928
[TBL] [Abstract][Full Text] [Related]
13. Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies.
Golshayan AR; Brick AJ; Choueiri TK
Future Oncol; 2008 Feb; 4(1):85-92. PubMed ID: 18241003
[TBL] [Abstract][Full Text] [Related]
14. An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting TKI-based therapy.
Galvano A; Guarini A; Iacono F; Castiglia M; Rizzo S; Tarantini L; Gori S; Novo G; Bazan V; Russo A
Expert Opin Drug Saf; 2019 Jun; 18(6):485-496. PubMed ID: 31062991
[TBL] [Abstract][Full Text] [Related]
15. The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors.
Tocchetti CG; Gallucci G; Coppola C; Piscopo G; Cipresso C; Maurea C; Giudice A; Iaffaioli RV; Arra C; Maurea N
Eur J Heart Fail; 2013 May; 15(5):482-9. PubMed ID: 23325019
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects.
Kappers MH; van Esch JH; Sleijfer S; Danser AH; van den Meiracker AH
J Hypertens; 2009 Dec; 27(12):2297-309. PubMed ID: 19680138
[TBL] [Abstract][Full Text] [Related]
17. Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugs.
Coppola C; Rienzo A; Piscopo G; Barbieri A; Arra C; Maurea N
Cancer Treat Rev; 2018 Feb; 63():135-143. PubMed ID: 29304463
[TBL] [Abstract][Full Text] [Related]
18. [Adverse cardiac effects associated with anticancer drugs].
Piuhola J; Tenhunen O; Kerkelä R
Duodecim; 2015; 131(5):441-7. PubMed ID: 26237906
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms.
Mulders P
BJU Int; 2009 Dec; 104(11):1585-9. PubMed ID: 20053190
[TBL] [Abstract][Full Text] [Related]
20. Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system.
Babiker HM; McBride A; Newton M; Boehmer LM; Drucker AG; Gowan M; Cassagnol M; Camenisch TD; Anwer F; Hollands JM
Crit Rev Oncol Hematol; 2018 Jun; 126():186-200. PubMed ID: 29759560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
